title: Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine.
abstract: Urothelial carcinoma (UC) is one of the most common cancers and survival rates are low in metastatic disease with currently established first-line platinum-based chemotherapies. Unlike in many other cancers, no clinically established molecular targeted therapies exist for the treatment of this malignancy. Here we present a case of complete tumor remission following third-line treatment with trastuzumab and gemcitabine in a patient with human epidermal growth factor receptor 2 (HER2)-positive UC after progression under cisplatin and vinflunine chemotherapies. This case shows the potential significance of anti-HER2 therapy in selected patients with molecularly characterized UC. Clinical trials so far show inconclusive outcomes of anti-HER2 therapies in UC, indicating further need for both basic research and clinical studies for the identification of resistance factors and improved patient selection.
authors.affiliation: Department of Urology, University of Ulm, Ulm, Germany.
authors.forename: Felix
authors.initials: F
authors.lastname: Wezel
authors.forename: Philipp
authors.initials: P
authors.lastname: Erben
authors.forename: Timo
authors.initials: T
authors.lastname: Gaiser
authors.forename: Johannes
authors.initials: J
authors.lastname: Budjan
authors.forename: Jost
authors.initials: J
authors.lastname: von Hardenberg
authors.forename: Maurice Stephan
authors.initials: MS
authors.lastname: Michel
authors.forename: Christian
authors.initials: C
authors.lastname: Bolenz
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000737:chemistry / Q000188:drug therapy* / Q000556:secondary*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D012074:Remission Induction; D000068878:Trastuzumab / Q000627:therapeutic use*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000074322:Antineoplastic Agents, Immunological; D003841:Deoxycytidine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D000093542:Gemcitabine; C508053:ERBB2 protein, human
keywords: Bladder; ERBB2 gene; Human epidermal growth factor receptor 2; Trastuzumab; Urothelial cancer